Twist Bioscience Corporation (NASDAQ:TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.
Analysts expect the South San Francisco, California-based company to report quarterly loss at 50 cents per share, versus a year-ago loss of 59 cents per share. The consensus estimate for Twist Bioscience’s quarterly revenue is $97.36 million, up from $84.71 million last year, according to data from Benzinga Pro.
On Aug. 4, Twist Bioscience issued FY25 sales guidance below estimates.
Shares of Twist Bioscience dipped 6.2% to close at $29.90 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Stephens & Co. analyst Steven Etoch initiated coverage on the stock with an Overweight rating and a price target of $41 on Nov. 4, 2025. This analyst has an accuracy rate of 65%.
- Goldman Sachs analyst Matthew Sykes maintained a Buy rating and cut the price target from $55 to $48 on May 6, 2025. This analyst has an accuracy rate of 66%.
- Guggenheim analyst Subbu Nambi reiterated a Buy rating with a price target of $50 on May 6, 2025. This analyst has an accuracy rate of 66%.
- Baird analyst Catherine Ramsey maintained an Outperform rating and lowered the price target from $54 to $44 on May 6, 2025. This analyst has an accuracy rate of 60%.
- JP Morgan analyst Rachel Vatnsdal maintained an Underweight rating and slashed the price target from $40 to $33 on May 6, 2025. This analyst has an accuracy rate of 70%
Considering buying TWST stock? Here’s what analysts think:
Photo via Shutterstock
